PubRank

Jayesh Mehta

Author PubWeight™ 65.53‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol 2010 2.69
2 Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006 2.32
3 Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011 2.07
4 Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003 1.81
5 A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma. Br J Haematol 2007 1.72
6 Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007 1.65
7 Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 2006 1.63
8 Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma 2009 1.50
9 Questioning the role of a neutropenic diet following hematopoetic stem cell transplantation. Biol Blood Marrow Transplant 2012 1.48
10 Impact of ABO mismatching on the outcomes of allogeneic related and unrelated blood and marrow stem cell transplantations for hematologic malignancies: IPD-based meta-analysis of cohort studies. Transfusion 2009 1.47
11 Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia. Leuk Res 2011 1.44
12 Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. Blood 2007 1.43
13 Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer 2009 1.42
14 Outcome of high-dose cytarabine-based induction therapy followed by hematopoietic stem cell transplantation in acute myeloid leukemia: influence of karyotype. Leuk Lymphoma 2008 1.39
15 Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2009 1.28
16 Hematopoietic growth factors pass through the blood-brain barrier in intact rats. Exp Neurol 2007 1.21
17 Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol 2008 1.10
18 Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis. J Immunol 2013 1.07
19 Recurrent aleukemic leukemia cutis in a patient with pre-B-cell acute lymphoblastic leukemia. J Clin Oncol 2013 1.05
20 The serum-free light chain assay cannot replace 24-hour urine protein estimation in patients with plasma cell dyscrasias. Blood 2007 1.04
21 DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer. Wiley Interdiscip Rev Syst Biol Med 2010 1.03
22 Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation. Antimicrob Agents Chemother 2009 1.03
23 Changing epidemiology of Clostridium difficile-associated disease during stem cell transplantation. Biol Blood Marrow Transplant 2012 1.03
24 The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios. Blood 2009 1.02
25 Beneficial effects of hematopoietic growth factor therapy in chronic ischemic stroke in rats. Stroke 2007 1.01
26 Brain repair by hematopoietic growth factors in a rat model of stroke. Stroke 2007 0.98
27 Bortezomib-induced tumor lysis syndrome in multiple myeloma. Clin Lymphoma Myeloma 2006 0.97
28 Immune reconstitution/immunocompetence in recipients of kidney plus hematopoietic stem/facilitating cell transplants. Transplantation 2015 0.96
29 First thalidomide clinical trial in multiple myeloma: a decade. Blood 2008 0.90
30 Novel therapies in multiple myeloma. Int J Hematol 2003 0.88
31 Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib. Blood 2010 0.86
32 One or two autografts for myeloma? Blood 2008 0.85
33 Latexin is down-regulated in hematopoietic malignancies and restoration of expression inhibits lymphoma growth. PLoS One 2012 0.84
34 Authorship limits. N Engl J Med 2002 0.83
35 Clinical significance of non-Candida fungal blood isolation in patients undergoing high-risk allogeneic hematopoietic stem cell transplantation (1993-2001). Cancer 2004 0.83
36 High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2008 0.82
37 Granulocyte-colony stimulating factor administration after myocardial infarction in a porcine ischemia-reperfusion model: functional and pathological effects of dose timing. Catheter Cardiovasc Interv 2007 0.81
38 Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection. FEMS Immunol Med Microbiol 2004 0.81
39 The role of posttransplantation maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukemia. Blood 2002 0.81
40 Risk of anaphylaxis with repeated courses of rasburicase: a Research on Adverse Drug Events and Reports (RADAR) project. Drug Saf 2015 0.79
41 Myeloid growth factors should not be administered routinely after allogeneic hematopoietic stem-cell transplantation. J Clin Oncol 2004 0.79
42 Easy to see but hard to find. N Engl J Med 2003 0.79
43 Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst 2009 0.78
44 Definition of myeloid engraftment after allogeneic hematopoietic stem cell transplantation. Haematologica 2004 0.77
45 F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma. Br J Haematol 2014 0.77
46 Haploidentical hematopoietic stem cell transplantation for graft-versus-host disease after liver transplantation. Blood 2011 0.77
47 Best practice guidelines for the management of adverse events associated with amphotericin B lipid complex. Expert Opin Drug Saf 2010 0.77
48 Regression of cardiac amyloid after autologous stem-cell transplantation. J Heart Lung Transplant 2009 0.77
49 Chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell transplantation: a little methotrexate goes a long way. J Clin Oncol 2002 0.77
50 Multiple myeloma. Clin J Am Soc Nephrol 2006 0.76
51 Infection--an underappreciated cause of bone pain in multiple myeloma. Br J Haematol 2003 0.76
52 Age and the outcome of allogeneic hematopoietic stem cell transplantation: was Tacitus wrong? Biol Blood Marrow Transplant 2011 0.76
53 A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings. Clin Adv Hematol Oncol 2007 0.76
54 Total therapy 2 in treatment of multiple myeloma: questions about gene expression profiling and treatment-related mortality. J Clin Oncol 2010 0.75
55 Hematopoietic stem cell transplantation from unrelated donors for acute leukemia. Blood 2008 0.75
56 Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc 2010 0.75
57 Induction therapy and outcome in acute myeloid leukemia. Cancer 2010 0.75
58 Routine tandem transplantation for patients with myeloma. Ann Intern Med 2003 0.75
59 Treatment for elderly patients with multiple myeloma. Lancet 2008 0.75
60 Varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 2002 0.75
61 Sirolimus-containing graft-versus-host disease prophylaxis in patients with lymphoma. J Clin Oncol 2009 0.75
62 PET-CT in lung cancer: data discrepancies. Thorax 2011 0.75
63 High-dose chemotherapy with autotransplantation in AL amyloidosis: a flawed meta-analysis. Biol Blood Marrow Transplant 2009 0.75
64 Instability of immunophenotype in plasma cell myeloma. Am J Clin Pathol 2008 0.75
65 Lenalidomide in myeloma. Curr Treat Options Oncol 2007 0.75
66 Sustained hematologic and central nervous system remission with single-agent denileukin diftitox in refractory adult T-cell leukemia/lymphoma. Clin Lymphoma Myeloma 2007 0.75
67 Idarubicin appears equivalent to dose-intense daunorubicin for remission induction in patients with acute myeloid leukemia. Leuk Res 2013 0.75
68 Re-use of the original infusional induction chemotherapy as salvage therapy in myeloma patients relapsing after one autograft. Hematology 2005 0.75
69 Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies. Leuk Lymphoma 2011 0.75
70 Variability of cyclosporine concentrations by HPLC and TDX monoclonal assay methods, application of a correction factor, and description of a novel clinical approach to determine the practical consequences of changing assay technique. Clin Transplant 2012 0.75
71 Treatment of relapsed and refractory multiple myeloma. Curr Treat Options Oncol 2003 0.75
72 Dose-intense etoposide-cyclophosphamide without stem cell transplantation for patients with intermediate and high cytogenetic risk primary refractory and relapsed acute myeloid leukemia. Leuk Res 2013 0.75
73 Recent developments and future directions in the treatment of multiple myeloma. Cancer Biother Radiopharm 2003 0.75
74 Diffuse large B-cell lymphoma: is there a place for autologous hematopoietic stem cell transplant in first remission in the era of chemo-immunotherapy? Leuk Lymphoma 2012 0.75